Feature | March 12, 2013

Mayo Study Questions if Imaging Agents Cause Acute Kidney Injury

Contrast Agents Mayo Clinic Clinical Study Kidney Injury

March 12, 2013 — Many physicians have long believed that the use of intravenous contrast agents for computed tomography (CT) scans can cause acute kidney injury. New Mayo Clinic research questions the strength of the causal link between the two. The findings from two tandem studies are published online in the journal Radiology.

The first study examined all previous research that compared patients who did or did not receive contrast agents, while the second paper represented a new retrospective study of over 100,000 CT scans performed at Mayo Clinic from 2000 to 2010, the largest published study to date examining the effect of contrast-enhanced imaging on renal function. In the retrospective study, researchers performed statistical analyses to study causality and mimic a randomized controlled trial to better match patients who received contrast agents to those patients who did not. These techniques had not been performed in any prior studies of renal function following contrast administration.

“These studies have significant clinical ramifications with regard to who is eligible to receive contrast media during CT exams,” says lead co-author Bob McDonald, M.D., Ph.D., a radiologist at Mayo Clinic. “Despite limited clinical evidence, contrast is commonly withheld during CT exams of individuals with even modest renal impairment due to concern for kidney injury, often at the expense of diagnostic accuracy of the exam. Our goal for these studies was to provide better evidence regarding the true incidence of renal injury following intravenous contrast administration and better define the ‘at-risk’ patient population.”

In both studies, Mayo Clinic researchers found that patients who received intravenous contrast agents and those who didn’t had a similar risk of developing acute kidney injury.

“Our findings suggest that, if contrast-induced nephropathy exists at all, it is likely rare and cannot be easily identified from unrelated causes of renal injury,” says lead co-author Jennifer McDonald, Ph.D., a radiology associate at Mayo Clinic. “Hopefully our findings can promote additional research to help redefine the safety window of contrast media and, in turn, improve patient care through more frequent use of appropriate clinical imaging.”

For more information: www.mayoclinic.org/about, www.mayoclinic.org/news

Related Content

Iodine-based CT contrast with ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs. It is not clear that contrast caused contract induced nephrapathy (CIN), also referred to as acute kidney injury (AKI) or contrast-associated acute kidney injury (CAAKI),

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.

Feature | Contrast Media | May 31, 2019 | Dave Fornell, Editor
Iodine-based contrast agents used in c
DyeMINISH Multi-center Global Patient Registry Launched
News | Contrast Media | May 09, 2019
Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety and...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
Overlay Init